Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL von Papadopoulou, A., Karavalakis, G., Papadopoulou, E., Xochelli, A., Bousiou, Z., Vogiatzoglou, A., Papayanni, P.G., Georgakopoulou, A., Giannaki, M., Stavridou, F., Vallianou, I., Kammenou, M., Varsamoudi, E., Papadimitriou, V., Giannaki, C., Sileli, M., Stergiouda, Z., Stefanou, G., Kourlaba, G., Triantafyllidou, M., Siotou, E., Karaglani, A., Zotou, E., Chatzika, G., Boukla, A., Apostolou, D., Pitsiou, G., Morfesis, P., Bartzoudis, D., Imprialos, K., Karampatakis, T., Kapravelos, N., Bitzani, M., Theodorakopoulou, M., Serasli, E., Sakellari, I., Fylaktou, A., Tryfon, S., Anagnostopoulos, A., Yannaki, E.

Volltext